Biosimilars are starting to make a significant impact in overall drug spending, which is what they are designed to do, said Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic.
Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains how interchangeable biosimilars are important—especially on the pharmacy benefit side—and serve as another step toward treating biosimilars like generic drugs.
Transcript
What is the predicted global drug spending by 2027?
It's estimated that by around 2027, the total global expenditures will be somewhere around $1.5 trillion. Oncology is probably going to be somewhere around $300 billion of that, and it's estimated that biosimilars will be somewhere in that 15% to maybe 20% range as far as total amount of the oncology biologics. I think it's gonna be a little hard to put an exact figure on what we're going to project by 2027 because some of it depends on uptake, how things change, what new ones come out between now and then. But they're starting to make a significant impact in the overall cost of drugs and that's what they're designed to do.
Why is the interchangeability designation so important for insulin biosimilars, like Rezvoglar and Semglee, for patients with diabetes?
Interchangeability is an interesting concept, and I think it's going to be more important for those drugs that are dispensed through retail pharmacies than they have been for the biosimilars, so far, that have been dispensed in infusion centers. In my institution and in a lot of institutions, we declare biosimilars therapeutically equivalent, and we have the ability to just change them out as we see fit. When you start getting into the retail setting, pharmacists don't have that authority unless they have a collaborative practice agreement with the provider. Interchangeability gives the pharmacist the choice to say, "This is the cheaper drug, this is the one we need, so let's go choose that one." So I think these interchangeables, particularly on the pharmacy benefit side, are going to be very, very important.
[There are] a whole lot of complexities that go along with them, because payers are making a lot of demands, formulary demands. What if the one you choose is not on the formulary? All of those kind of complicated things are going to get in there. But I do think that these new interchangeables are the first step to get us to the point where, from a policy perspective, we start treating biosimilars like generic drugs.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More